Marilyne Labrie Selected Research

Marilyne Labrie Research Topics

Disease

21	Neoplasms (Cancer) 05/2024 - 01/2013
11	Breast Neoplasms (Breast Cancer) 10/2023 - 01/2013
9	Ovarian Neoplasms (Ovarian Cancer) 05/2024 - 09/2014
2	Neoplasm Metastasis (Metastasis) 05/2024 - 04/2014
2	Glioma (Gliomas) 01/2022 - 12/2021
2	Bites and Stings (Sting) 10/2021 - 01/2019
1	Lung Neoplasms (Lung Cancer) 05/2024
1	Residual Neoplasm 05/2022
1	Pathologic Complete Response 05/2022
1	Endometrial Neoplasms (Endometrial Cancer) 12/2021
1	Triple Negative Breast Neoplasms 10/2021
1	Melanoma (Melanoma, Malignant) 01/2021
1	DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes) 01/2019
1	Carcinoma (Carcinomatosis) 10/2017
1	Disease Progression 04/2016
1	Prostatic Neoplasms (Prostate Cancer) 01/2015
1	Glioblastoma (Glioblastoma Multiforme) 12/2013
1	Nervous System Diseases (Neurological Disorders) 12/2013
1	Alzheimer Disease (Alzheimer's Disease) 12/2013
1	Multiple Sclerosis 12/2013

Drug/Important Bio-Agent (IBA)

8	Proteins (Proteins, Gene)FDA Link 10/2021 - 01/2013
6	Galectins (Galectin)IBA 10/2017 - 01/2013
5	Poly(ADP-ribose) Polymerase InhibitorsIBA 05/2022 - 01/2019
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 02/2018
2	Trastuzumab (Herceptin)FDA Link 10/2023 - 01/2021
2	Estrogen ReceptorsIBA 10/2023 - 01/2013
2	Biomarkers (Surrogate Marker)IBA 05/2022 - 10/2017
2	talazoparibIBA 05/2022 - 05/2019
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2019
2	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 12/2021
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 10/2021 - 10/2019
2	ApolipoproteinsIBA 10/2019 - 02/2018
2	Apolipoproteins E (ApoE)IBA 02/2018 - 12/2013
2	Messenger RNA (mRNA)IBA 01/2014 - 01/2013
1	ChromatinIBA 05/2024
1	Immune Checkpoint ProteinsIBA 05/2024
1	ProteomeIBA 10/2023
1	Gentian Violet (Violet, Crystal)FDA Link 01/2022
1	alpha-2'-deoxythioguanosineIBA 12/2021
1	NucleosidesIBA 12/2021
1	olaparibIBA 12/2021
1	capivasertibIBA 12/2021
1	Sirolimus (Rapamycin)FDA Link 01/2021
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2021
1	dactolisibIBA 01/2021
1	Therapeutic UsesIBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 01/2019
1	CytokinesIBA 02/2018
1	Matrix Metalloproteinases (MMPs)IBA 02/2018
1	Focal Adhesion Protein-Tyrosine KinasesIBA 02/2018
1	AminopropionitrileIBA 02/2018
1	Inosine FDA Link 01/2018
1	NucleotidesIBA 01/2018
1	Adenosine (Adenocard)FDA LinkGeneric 01/2018
1	immune RNA (I-RNA)IBA 01/2018
1	AntigensIBA 10/2017
1	1-nitrohydroxyphenyl-N-benzoylalanine (GAL 1)IBA 04/2016
1	Cisplatin (Platino)FDA LinkGeneric 01/2015
1	CarbohydratesIBA 01/2015
1	Etoposide (VP 16)FDA LinkGeneric 01/2015
1	Phenobarbital (Luminal)FDA Link 11/2014
1	matrigelIBA 09/2014
1	LigandsIBA 04/2014
1	GlycoconjugatesIBA 04/2014
1	Protein Isoforms (Isoforms)IBA 01/2014
1	CCAAT-Enhancer-Binding ProteinsIBA 01/2014
1	Apolipoproteins D (Apo D)IBA 12/2013
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 09/2013
1	EnzymesIBA 09/2013
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2013

Therapy/Procedure

13	Therapeutics 05/2024 - 04/2014
3	Immunotherapy 10/2021 - 01/2019
2	Drug Therapy (Chemotherapy) 01/2019 - 10/2017
1	Investigational Therapies (Experimental Therapy) 01/2022